Technology Innovation, People Centric
Adhering to the mission of providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, Endovastec™ is committed to building a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
Products
Endovastec™ focuses on the research and development (R&D), manufacturing, sales and services of aortic, peripheral vascular and tumor intervention devices,and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated balloon dilatation catheters, balloon dilatation catheters, vena cava filters and snare retrieval kits etc.
News

Endovastec™ Announces Annual Results for 2025: Solid Growth with Continued Innovation and Global Expansion
The Company continued to advance its dual strategic of innovation-driven growth and global expansion, maintaining steady and positive business performance.
30 Mar 2026


FDA Grants Breakthrough Device Designation to Endovastec™’s Hector™ Multi-Branch Thoracic Stent Graft System
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Hector™ Multi-Branch Thoracic Stent Graft System (“Hector™”), an investigational device designed for the endovascular treatment of complex aortic arch disease.
13 Mar 2026

.png)
Endovastec™ Completes First Commercial Use of Minos™ in the Netherlands
Endovastec™ recently announced the first two commercial uses of its Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™) in the Netherlands.
26 Sept 2025
